SLAM
APGE icon

Swiss Life Asset Management’s Apogee Therapeutics APGE Stock Holding History

Swiss Life Asset Management’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$290K Buy
+2,183
New +$197K ﹤0.01% 1287

Other funds holding APGE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $80B AUM 26.12% 1-Year Est. Return
RCP
Remedium Capital Partners Fort Lauderdale, Florida $452M AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
MSE
MUFG Securities EMEA London, United Kingdom $9.53B AUM 52.96% 1-Year Est. Return
PMAM
Picton Mahoney Asset Management Toronto, Ontario, Canada $13.5B AUM 51.47% 1-Year Est. Return

Swiss Life Asset Management's APGE Position: Q2 2026 in Review

Swiss Life Asset Management opened a new position in Apogee Therapeutics (APGE) in Q2 2026: 2,183 shares worth $290K. The stake represents ﹤0.01% of the portfolio and ranks #1287 among its holdings.

138 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Swiss Life Asset Management held 2,183 shares of Apogee Therapeutics worth $290K as of Q2 2026.
  • Apogee Therapeutics was a new Swiss Life Asset Management position in Q2 2026.
  • Apogee Therapeutics made up ﹤0.01% of Swiss Life Asset Management's portfolio in Q2 2026, its #1287 holding.
  • 138 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Swiss Life Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.